Ramelteon
Ramelteon is a central nervous system (CNS) depressant medication that can help people sleep. It is used for patients that have trouble falling asleep.
Ramelteon has significant drug-drug interaction with the following drugs: .
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Rozerem, others |
| Synonyms | TAK-375 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605038 |
| License data | |
| Dependence liability | Low[1] |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 1.8%[3] |
| Protein binding | 82% (mainly albumin)[3] |
| Metabolism | Liver (CYP1A2 major, CYP2C and CYP3A4 minor)[3] |
| Metabolites | M-II (active metabolite)[3] |
| Elimination half-life | Ramelteon: 1–2.6 hours[3] M-II: 2–5 hours[3][4] |
| Excretion | Kidney: 84%[3] Feces: 4%[3] |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | |
| ECHA InfoCard | |
| Chemical and physical data | |
| Formula | C16H21NO2 |
| Molar mass | 259.35 g·mol−1 |
| 3D model (JSmol) | |
| (verify) | |
Expression error: Unexpected < operator.Expression error: Unexpected < operator.Expression error: Unexpected < operator.
References
- ↑ Kim, HK. Melatonin and melatonergic drugs in sleep disorders.. Translational and Clinical Pharmacology 30 (4) (December 2022). p. 163–171. doi:10.12793/tcp.2022.30.e21.
- ↑ Anvisa. [https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial] (in pt-BR) (2023-03-31)Diário Oficial da União. Retrieved 2023-08-16.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Cite error: Invalid
<ref>tag; no text was provided for refs namedRozerem FDA label. - ↑ Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. Journal of Clinical Pharmacology 46 (2) (February 2006). p. 140–148. doi:10.1177/0091270005283461.
